Antiangiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoediting

References

• HarzstarkALSmallEJImmunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge)Expert Opin Biol Ther200771275128017696825
   PubMed Web of Science ®Google Scholar
• RosenbergSARestifoNPYangJCMorganRADudleyMEAdoptive cell transfer: a clinical path to effective cancer immunotherapyNat Rev Cancer2008829930818354418
   PubMed Web of Science ®Google Scholar
• WoodLMGuirnaldaPDSeaveyMMPatersonYCancer immunotherapy using Listeria monocytogenes and listerial virulence factorsImmunol Res20084223324519018479
   PubMed Web of Science ®Google Scholar
• HussainSFPatersonYWhat is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumorsCancer Immunol Immunother20055457758615650885
   PubMed Web of Science ®Google Scholar
• SeaveyMMPanZKMaciagPC A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumorsClin Cancer Res20091592493219188163
   PubMed Web of Science ®Google Scholar
• ShahabiVReyes-ReyesMWallechaARiveraSPatersonYMaciagPCDevelopment of a Listeria monocytogenes based vaccine against prostate cancerCancer Immunol Immunother2008571301131318273616
   PubMed Web of Science ®Google Scholar
• SinghRDominieckiMEJaffeeEMPatersonYFusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouseJ Immunol20051753663367316148111
   PubMed Web of Science ®Google Scholar
• SinghRPatersonYVaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancerCancer Res2006667748775716885378
   PubMed Web of Science ®Google Scholar
• SoudersNCSewellDAPanZK Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancerCancer Immun20077217279610
   PubMedGoogle Scholar
• BaiXFLiuJLiOZhengPLiuYAntigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytesJ Clin Invest20031111487149612750398
   PubMed Web of Science ®Google Scholar
• SinghRPatersonYImmunoediting sculpts tumor epitopes during immunotherapyCancer Res2007671887189217332314
   PubMed Web of Science ®Google Scholar
• PothlichetJHeidmannTMangeneyMA recombinant endogenous retrovirus amplified in a mouse neuroblastoma is involved in tumor growth in vivoInt J Cancer Suppl2006119815822
   Google Scholar
• SeaveyMMMaciagPCAl-RawiNSewellDPatersonYAn antivascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse modelJ Immunol20091825537554619380802
   PubMed Web of Science ®Google Scholar
• ParkDIKangMSOhSJ HER-2/neu overexpression is an independent prognostic factor in colorectal cancerInt J Colorectal Dis20072249149716947041
   PubMed Web of Science ®Google Scholar
• SannaGFranceschelliLRotmenszN Brain metastases in patients with advanced breast cancerAnticancer Res2007272865286917695462
   PubMed Web of Science ®Google Scholar
• GaedckeJTraubFMildeS Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancerMod Pathol20072086487017541441
   PubMed Web of Science ®Google Scholar
• MataMYaoZJZubairASyresKPatersonYEvaluation of a recombinant Listeria monocytogenes expressing an HIV protein that protects mice against viral challengeVaccine2001191435144511163666
   PubMed Web of Science ®Google Scholar
• LuoYMarkowitzDXiangRZhouHReisfeldRAFlk-1-based minigene vaccines induce T cell-mediated suppression of angiogenesis and tumor protective immunity in syngeneic BALB/c miceVaccine2007251409141517113202
   PubMed Web of Science ®Google Scholar
• MaciagPCSeaveyMMPanZKFerroneSPatersonYCancer immu-notherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculatureCancer Res2008688066807518829565
   PubMed Web of Science ®Google Scholar
• PengXTremlJPatersonYAdjuvant properties of listeriolysin O protein in a DNA vaccination strategyCancer Immunol Immunother20075679780617102978
   PubMed Web of Science ®Google Scholar
• ShahabiVReyes-ReyesMWallechaARiveraSPatersonYMaciagPCDevelopment of a Listeria monocytogenes based vaccine against prostate cancerCancer Immunol Immunother2008571301131318273616
   PubMed Web of Science ®Google Scholar
• SchlegelJTrenkleTStummGKiesslingMGrowth inhibition by dominant-negative mutations of the neu-encoded oncoproteinInt J Cancer Suppl1997707883
   Google Scholar
• BurgessAWEGFR family: structure physiology signalling and therapeutic targetsGrowth Factors20082626327418800267
   PubMed Web of Science ®Google Scholar
• SinghRPatersonYIn the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccinesCancer Immunol Immunother20075692793817131121
   PubMed Web of Science ®Google Scholar
• HuntzickerEGEstayISZhenHLoktevaLAJacksonPKOroAEDual degradation signals control Gli protein stability and tumor formationGenes Dev20062027628116421275
   PubMed Web of Science ®Google Scholar
• YueSChenYChengSYHedgehog signaling promotes the degradation of tumor suppressor Sufu through the ubiquitin-proteasome pathwayOncogene20092849249918997815
   PubMed Web of Science ®Google Scholar
• ChangCCCampoliMRestifoNPWangXFerroneSImmune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapyJ Immunol20051741462147115661905
   PubMed Web of Science ®Google Scholar
• QuesnelAHsuSCDelmasAStewardMWTrudelleYAbastadoJPEfficient binding to the MHC class I K(d) molecule of synthetic peptides in which the anchoring position 2 does not fit the consensus motifFEBS Lett199638742468654564
   PubMed Web of Science ®Google Scholar
• TianJGregoriSAdoriniLKaufmanDLThe frequency of high avidity T cells determines the hierarchy of determinant spreadingJ Immunol20011667144715011390460
   PubMed Web of Science ®Google Scholar
• ChenJDengYMInfluenza viral antigen variation, host antibody production and new approach to control epidemicsVirol J200963019284639
   PubMed Web of Science ®Google Scholar
• PhamVPRothmanPBGottesdienerKMBinding of trans-acting factors to the double-stranded variant surface glycoprotein (VSG) expression site promoter of Trypanosoma bruceiMol Biochem Parasitol19978911239297697
   PubMed Web of Science ®Google Scholar
• PukropTKlemmFHagemannT Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell linesProc Natl Acad Sci U S A20061035454545916569699
   PubMed Web of Science ®Google Scholar
• De LarcoJEWuertzBRFurchtLTThe potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8Clin Cancer Res2004104895490015297389
   PubMed Web of Science ®Google Scholar
• MittendorfEAGurneyJMStorrerCEShriverCDPonniahSPeoplesGEVaccination with a HER-2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancerSurgery2006139340741816546506
   PubMed Web of Science ®Google Scholar
• ButterfieldLHRibasADissetteVB Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanomaClin Cancer Res200493998100812631598
   PubMed Web of Science ®Google Scholar
• WallechaAMaciagPCRiveraSPatersonYShahabiVConstruction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapyClin Vaccine Immunol20091619610319020110
   PubMed Web of Science ®Google Scholar